Latest filing published 10 Jul 2023 for Adaptimmune Therapeutics PLC, €39k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Garry E. Menzel: trading record in brief
Filings by Garry E. Menzel span 3 companies, the busiest being TCR2 Therapeutics Inc., Adaptimmune Therapeutics PLC and Black Diamond Therapeutics, Inc. Between 30 August 2019 and 10 July 2023, the trades on record add up to 30 filings.
On the market, this insider has only sold: 9 sales, €136k in total. Other entries cover 9 share grants and 2 option exercises. 2023 to date brings no purchases and 1 sale.
On 10 July 2023 came the latest disclosure, an open-market sale for €39k in Adaptimmune Therapeutics PLC. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Garry E. Menzel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 47,702 shares@ US$0.9108100.0% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-079700:0
- 132,729 sharesCommon StockSEC:0001104659-23-067053:0
- 200,646 sharesAmerican Depositary Shares representing Ordinary SharesSEC:0001104659-23-067118:0
- 10,325 shares@ US$1.13123.8% of flowCommon StockSEC:0000899243-22-038380:0
- 9,111 shares@ US$1.28224.0% of flowCommon StockSEC:0000899243-22-038098:0
- 8,530 shares@ US$1.37223.9% of flowCommon StockSEC:0000899243-22-037941:0
- 221,058 sharesCommon StockSEC:0001209191-22-059881:0
- 84,527 shares0Common StockSEC:0000899243-22-029864:0
- 1,425 shares@ US$2.307.1% of flowCommon StockSEC:0001209191-22-020025:0
- 422 shares@ US$14.2612.3% of flowCommon StockSEC:0001209191-21-069050:0
10 of 10 declarations
